Other
Attention
0
Pipeline Programs↗
13
Active Trials↗
9
Companies Involved↗
Attention is an early-stage landscape with 0 programs across 9 companies. The most active players are Eli Lilly, Johnson & Johnson, Tris Pharma, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
62
clinical trials
Completed41 · 66%
Recruiting10 · 16%
Unknown status5 · 8%
Not yet recruiting3 · 5%
Withdrawn2 · 3%
Terminated1 · 2%
Clinical Trials
Trial Activity
62 trials
The Effect of Oral Oxytocin and Atosiban on Social Attention
Recruiting·UUniversity of Electronic Science and Technology of China·Phase 1·NCT07093060·250 enrolled
Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3
Recruiting·—·N/A·NCT06669585·64 enrolled
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
Recruiting·UUniversity of Electronic Science and Technology of China·Phase 1·NCT07140237·250 enrolled
Training Inhibitory Control Using Personalized Strategies (TIPS): A Randomized Controlled Feasibility Trial of a Smartphone-Based Intervention for Alcohol Use in Young Adults With ADHD
Recruiting·—·Preclinical·NCT07654205·70 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)